Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Return on Sales (2016 - 2021)

Syndax Pharmaceuticals (SNDX) has 7 years of Return on Sales data on record, last reported at 52.26% in Q3 2021.

  • For Q3 2021, Return on Sales rose 12.0% year-over-year to 52.26%; the TTM value through Sep 2021 reached 52.26%, down 891.0%, while the annual FY2025 figure was 1.45%, 1179.0% up from the prior year.
  • Return on Sales reached 52.26% in Q3 2021 per SNDX's latest filing, roughly flat from 52.32% in the prior quarter.
  • Across five years, Return on Sales topped out at 15.95% in Q4 2017 and bottomed at 52.38% in Q3 2020.
  • Average Return on Sales over 5 years is 44.54%, with a median of 47.07% recorded in 2018.
  • Peak YoY movement for Return on Sales: skyrocketed 1970bps in 2017, then plummeted -3493bps in 2018.
  • A 5-year view of Return on Sales shows it stood at 15.95% in 2017, then plummeted by -219bps to 50.88% in 2018, then rose by 27bps to 37.38% in 2019, then tumbled by -40bps to 52.26% in 2020, then changed by 0bps to 52.26% in 2021.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 52.26% in Q3 2021, 52.32% in Q2 2021, and 49.49% in Q1 2021.